The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients
Clinical Transplantation · 2024
DOI: 10.1111/ctr.70050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Jeanne M Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, IU Health, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Basiliximab, Pancreas Transplantation, Immunosuppressive Agents, Graft Rejection. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This single‐center retrospective study was designed to evaluate the use of basiliximab as an alternative rescue maintenance immunosuppression in situations where standard maintenance immunosuppression is not tolerated after a pancreas transplant. All pancreas transplants performed between January 11, 2006, and January 6, 2022, were reviewed. All recipients received rabbit antithymocyte globulin (rATG) induction with tacrolimus + sirolimus maintenance for simultaneous pancreas and kidney (SPK) and additional low‐dose mycophenolic acid for pancreas transplant alone (PTA). Basiliximab 40mg IV q 4 weeks was either added to or in replacement of adjunct immunosuppression in cases of medication intolerance. All recipients who received ≥3 months of basiliximab with ≥1 year follow‐up were included. 29/557 (5.2%) recipients (5 SPK and 24 PTA) were identified. Median time to switch was 13 months. When compared 1:2 to matched controls on standard immunosuppression, there was no difference in pancreas rejection, allograft loss, or mortality. Eleven recipients had 13 episodes of pancreas rejection at a median of 28 months post conversion. Eight pancreas allografts failed at a median of 28 months post conversion, and there were five deaths—all occurring in PTA, 4/5 occurring ≥1 year after discontinuation of basiliximab. Renal allograft rejection occurred in one SPK and there was one renal allograft loss. Five PTA developed renal failure. Ten remain on basiliximab (2/5 SPK, 8/24 PTA) at a median of 44 months with good pancreas and kidney function; 4 pts > 4 years. Basiliximab can be considered an alternative rescue maintenance strategy in pancreas transplant recipients who failed other conventional agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, IU Health, Indianapolis, Indiana, USA.
- Department of Surgery, IU Health/Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Nephrology, IU Health/Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Jeanne M Chen, Richard S Mangus, Oluwafisayo O Adebiyi, Jonathan A Fridell
Zitieren
APA
Chen, J. M., Mangus, R. S., Sharfuddin, A. A., Powelson, J. A., Yaqub, M. S., Adebiyi, O. O., Jan, M. Y., Lutz, A. J., & Fridell, J. A. (2024). The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70050
Vancouver
Chen JM, Mangus RS, Sharfuddin AA, Powelson JA, Yaqub MS, Adebiyi OO, et al. The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.70050
BibTeX
@article{Chen2024,
author = {Chen, Jeanne M and Mangus, Richard S and Sharfuddin, Asif A and Powelson, John A and Yaqub, Muhammad S and Adebiyi, Oluwafisayo O and Jan, Muhammad Y and Lutz, Andrew J and Fridell, Jonathan A},
title = {The Use of Long‐Term Monthly Basiliximab Infusions as Rescue Maintenance Immunosuppression in Pancreas Transplant Recipients},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.70050}
}
EUVIMED